HCC risk in patients with HBV-related cirrhosis receiving nucleos(t)ide analogues therapy: Is HCC prevented or delayed?

Tung-Hung Su^{1

2}, Tai-Chung Tseng^{1

2

3}, Jia-Horng Kao^{1

2

4

5}

Affiliations

¹ Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
² Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
³ Department of Internal Medicine, National Taiwan University Hospital Jinshan Branch, New Taipei City, Taiwan.
⁴ Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
⁵ Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.

Comment

Tung-Hung Su et al. Hepatology. 2018 Apr.

. 2018 Apr;67(4):1634-1635.

doi: 10.1002/hep.29740. Epub 2018 Feb 27.

Tung-Hung Su^{1

2}, Tai-Chung Tseng^{1

2

3}, Jia-Horng Kao^{1

2

4

5}

¹ Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
² Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
³ Department of Internal Medicine, National Taiwan University Hospital Jinshan Branch, New Taipei City, Taiwan.
⁴ Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
⁵ Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.

No abstract available

Comment on

Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus-endemic population.
Choi J, Han S, Kim N, Lim YS. Choi J, et al. Hepatology. 2017 Nov;66(5):1454-1463. doi: 10.1002/hep.29321. Epub 2017 Oct 11. Hepatology. 2017. PMID: 28628942